-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
WuXi Biologics (Cayman) Inc. (HKG:2269) Insiders Placed Bullish Bets Worth CN¥98m in the Last 12 Months
WuXi Biologics (Cayman) Inc. (HKG:2269) Insiders Placed Bullish Bets Worth CN¥98m in the Last 12 Months
In the last year, multiple insiders have substantially increased their holdings of WuXi Biologics (Cayman) Inc. (HKG:2269) stock, indicating that insiders' optimism about the company's prospects has increased.
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
Check out our latest analysis for WuXi Biologics (Cayman)
WuXi Biologics (Cayman) Insider Transactions Over The Last Year
Over the last year, we can see that the biggest insider purchase was by CEO & Executive Director Zhisheng Chen for HK$39m worth of shares, at about HK$104 per share. That means that even when the share price was higher than HK$47.40 (the recent price), an insider wanted to purchase shares. While their view may have changed since the purchase was made, this does at least suggest they have had confidence in the company's future. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels. We note that Zhisheng Chen was both the biggest buyer and the biggest seller.
Over the last year, we can see that insiders have bought 1.02m shares worth HK$98m. On the other hand they divested 299.83k shares, for HK$20m. In total, WuXi Biologics (Cayman) insiders bought more than they sold over the last year. You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. By clicking on the graph below, you can see the precise details of each insider transaction!
SEHK:2269 Insider Trading Volume October 2nd 2022WuXi Biologics (Cayman) is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
Insider Ownership
For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Insiders own 0.3% of WuXi Biologics (Cayman) shares, worth about HK$605m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.
So What Does This Data Suggest About WuXi Biologics (Cayman) Insiders?
The fact that there have been no WuXi Biologics (Cayman) insider transactions recently certainly doesn't bother us. On a brighter note, the transactions over the last year are encouraging. It would be great to see more insider buying, but overall it seems like WuXi Biologics (Cayman) insiders are reasonably well aligned (owning significant chunk of the company's shares) and optimistic for the future. Of course, the future is what matters most. So if you are interested in WuXi Biologics (Cayman), you should check out this free report on analyst forecasts for the company.
But note: WuXi Biologics (Cayman) may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions, but not derivative transactions.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
去年,多位内部人士大幅增加了持有的股份 药明生物制剂(开曼)有限公司 (HKG: 2269) 股票,表明内部人士对公司前景的乐观情绪有所增加。
尽管在长期投资中,内幕交易并不是最重要的事情,但逻辑要求你应该注意内部人士是在买入还是卖出股票。
查看我们对药明生物制剂(开曼)的最新分析
药明生物制剂(开曼)去年的内幕交易
在过去的一年中,我们可以看到,最大的内幕收购是首席执行官兼执行董事陈智胜以价值3,900万港元的股票,每股约104港元。这意味着,即使股价高于47.40港元(近期价格),内部人士也想购买股票。尽管自收购以来,他们的看法可能发生了变化,但这至少表明他们对公司的未来充满信心。对我们来说,考虑内部人士为股票支付的价格非常重要。如果他们支付的费用高于当前价格,通常会更令人鼓舞,因为这表明即使在更高的水平上他们也看到了价值。我们注意到,陈智胜既是最大的买家,也是最大的卖家。
在过去的一年中,我们可以看到内部人士购买了价值98万港元的102万股股票。另一方面,他们以2,000万港元剥离了299.83万股股票。总的来说,药明生物制剂(开曼)内部人士的购买量超过了去年的销售额。您可以看到下图所示的去年的内幕交易(公司和个人)。通过点击下面的图表,你可以看到每笔内幕交易的确切细节!
SEHK: 2269 2022 年 10 月 2 日内幕交易量无锡生物制剂(开曼)并不是内部人士买入的唯一股票。对于那些喜欢寻找的人 获胜的投资 这个 免费的 最近进行内幕收购的成长型公司名单可能只是门票。
内部所有权
对于普通股股东来说,值得检查一下公司内部人士持有多少股份。通常,内部所有权越高,内部人士被激励长期建立公司的可能性就越大。业内人士拥有药明生物制剂(开曼)0.3%的股份,价值约6.05亿港元。这种内部所有权水平不错,但还不算特别突出。这无疑表明了合理程度的一致性。
那么,这些数据对药明生物制剂(开曼)内部人士有什么启示呢?
最近没有药明生物制剂(开曼)内幕交易这一事实当然不会打扰我们。好消息是,去年的交易令人鼓舞。看到更多的内幕买盘真是太好了,但总体而言,无锡生物制药(开曼)的内部人士似乎相当一致(拥有该公司的大部分股份),对未来持乐观态度。当然, 未来才是最重要的。因此,如果你对药明生物制剂(开曼)感兴趣,你应该看看这个 免费的 分析师对公司的预测报告。
但请注意: 药明生物制剂(开曼)可能不是最值得买入的股票。所以来看看这个 免费的 投资回报率高、负债低的有趣公司名单。
就本文而言,内部人士是指向相关监管机构报告交易的个人。我们目前用于公开市场交易和私人处置,但不包括衍生品交易。
对这篇文章有反馈吗?对内容感到担忧? 取得联系 直接和我们联系。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是一般性的。 我们仅使用不偏不倚的方法根据历史数据和分析师预测提供评论,我们的文章并非旨在提供财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能未将最新的价格敏感型公司公告或定性材料考虑在内。简而言之,华尔街对上述任何股票都没有头寸。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧